ACTUATE THERAPEUTICS (ACTU) director receives grant of 15,000 stock options

Rhea-AI Filing Summary

ACTUATE THERAPEUTICS, INC. director Jason A. Keyes received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036. According to the footnote, the options will vest in full on the first anniversary of the grant date, meaning Keyes must remain eligible through that date before the award is fully exercisable. Following this grant, his reported derivative holdings from this award total 15,000 stock options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Keyes Jason A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	15,000	$0.00	--

Holdings After Transaction: Stock Options — 15,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 15,000 options Exercise price: $2.4200 per share Expiration date: May 21, 2036 +2 more

5 metrics

Stock options granted 15,000 options Grant of stock options to director Jason A. Keyes

Exercise price $2.4200 per share Exercise price for the stock options

Expiration date May 21, 2036 Options expiration for this award

Underlying shares 15,000 shares Common stock underlying the options

Total derivative holdings after grant 15,000 options Total stock options from this award after transaction

Key Terms

Stock Options, Common Stock, Grant, award, or other acquisition, vest in full

4 terms

Stock Options financial

"The options have an exercise price of $2.4200 per share and expire"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Common Stock financial

"stock options covering 15,000 shares of common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction code is A, described as a grant, award, or other acquisition"

vest in full financial

"Options will vest in full on the anniversary of the grant date"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keyes Jason A

(Last) (First) (Middle)

C/O ACTUATE THERAPEUTICS, INC.

1751 RIVER RUN, SUITE 400

(Street)

FT WORTH TEXAS 76107

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACTUATE THERAPEUTICS, INC. [ ACTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$2.42	05/21/2026		A		15,000		(1)	05/21/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. Options will vest in full on the anniversary of the grant date.

	/s/ Paul Lytle, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ACTU director Jason A. Keyes receive in this Form 4 for ACTU?

Jason A. Keyes received a grant of stock options for 15,000 shares of ACTU common stock. These options were awarded at no cost on the grant date and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Jason Keyes’ new ACTU stock options?

The exercise price of Jason Keyes’ stock options is $2.4200 per share. This is the price at which he can purchase ACTU common stock once the options vest and remain exercisable until they reach their expiration date.

When do Jason Keyes’ ACTU stock options vest and expire?

The options will vest in full on the anniversary of the grant date, as disclosed in the footnote. They are scheduled to expire on May 21, 2036, giving a long window during which vested options can potentially be exercised.

How many ACTU stock options does Jason Keyes hold after this transaction?

Following this award, Jason Keyes is reported as holding 15,000 stock options from this grant. The Form 4 shows total derivative securities following the transaction equal to 15,000, all tied to ACTU common stock as the underlying security.

Is Jason Keyes’ ACTU Form 4 transaction a market purchase or sale?

No, this Form 4 reflects a grant or award acquisition, not an open-market trade. The transaction code is A, described as a grant, award, or other acquisition of derivative securities, with no reported buying or selling in the open market.